Middletown Life

Author: Ascelia Pharma

Change in Number of Shares and Votes in Ascelia Pharma AB

April 30, 2026
Annual Report 2025: Orviglance NDA submitted to the FDA, PDUFA-date set for July 2026

April 9, 2026
Notice of Annual General Meeting in Ascelia Pharma AB

March 30, 2026
Ascelia Pharma Announces Acceptance of Orviglance Data for Oral Presentation at the Annual Radiology Congress ESGAR 2026

March 27, 2026
Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for Review

February 12, 2026
Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company

January 21, 2026
Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB

December 22, 2025